Forte Biosciences Inc. (FBRX)
NASDAQ: FBRX
· Real-Time Price · USD
11.35
0.76 (7.18%)
At close: Jun 26, 2025, 3:59 PM
10.79
-4.93%
After-hours: Jun 26, 2025, 06:09 PM EDT
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.
The company is headquartered in Dallas, Texas.
Forte Biosciences Inc.
| Country | United States |
| IPO Date | Apr 13, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Dr. Paul A. Wagner Ph.D. |
Contact Details
Address: 3060 Pegasus Park Drive Dallas, Texas United States | |
| Website | https://www.fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G2084 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President & Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Christopher Roenfeldt | Chief Operating Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | 424B5 | Filing |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 424B5 | Filing |
| Jun 23, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 30, 2025 | ARS | Filing |